Cargando…

Dosing practice of low molecular weight heparins and its efficacy and safety in cardiovascular inpatients: a retrospective study in a Chinese teaching hospital

BACKGROUND: Low-molecular-weight heparins (LMWHs) are safe and effective anticoagulant options for cardiovascular patients when applied as body weight-adjusted doses. However, there are some barriers that make it difficult to implement weight-adjusted doses in clinical practice. Therefore, it is vit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Huimin, Cai, Hongwen, Qian, Zhongshu, Xu, Geng, Yan, Xiaofeng, Dai, Haibin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3538057/ https://www.ncbi.nlm.nih.gov/pubmed/23217192 http://dx.doi.org/10.1186/1471-2261-12-118

Ejemplares similares

Pharmacist care and the management of coronary heart disease: a systematic review of randomized controlled trials
por: Cai, Hongwen, et al.
Publicado: (2013)

Safety of intermediate dose of low molecular weight heparin in COVID-19 patients
por: Mattioli, Massimo, et al.
Publicado: (2020)

Effectiveness, safety, and costs of thromboprophylaxis with enoxaparin or unfractionated heparin in inpatients with obesity
por: Amin, Alpesh, et al.
Publicado: (2023)

The efficacy and safety of low-molecular-weight heparin and unfractionated heparin in the treatment of cerebral venous sinus thrombosis
por: Afshari, Daryoush, et al.
Publicado: (2015)

Safety of low-molecular-weight heparin compared to unfractionated heparin in hemodialysis: a systematic review and meta-analysis
por: Lazrak, Hind Harrak, et al.
Publicado: (2017)

Comparison of the efficacy and safety of rivaroxaban and low-molecular-weight heparin in Chinese lung cancer patients with nonhigh-risk pulmonary embolism
por: Song, Yijun, et al.
Publicado: (2023)

Outcomes of thromboprophylaxis with enoxaparin vs. unfractionated heparin in medical inpatients
por: McGarry, Lisa J, et al.
Publicado: (2006)

Heparin/low molecular weight heparins: Thrombocytopenia: 7 case reports
Publicado: (2021)

Therapeutically dosed low molecular weight heparins in renal impairment: a nationwide survey
por: Jaspers, Tessa Corrine Catherina, et al.
Publicado: (2022)

Efficacy and safety of low-dose aspirin combined with low-molecular-weight heparin in treatment of preeclampsia: a meta-analysis and systematic review
por: Wu, Chunfeng, et al.
Publicado: (2021)

Bleeding and Thrombotic Risk in Low Dose Heparin Infusion as Compared to Standard Dose Heparin Infusion
por: Lutfi, Forat, et al.
Publicado: (2020)

Characteristics of Infective Endocarditis in a Tertiary Hospital in East China
por: Xu, Huimin, et al.
Publicado: (2016)

Low molecular weight heparin is useful in adult COVID-19 inpatients. Experience during the first Spanish wave: observational study
por: Gonzalez-Porras, Jose Ramon, et al.
Publicado: (2021)

Safety and Feasibility of Subcutaneous Low Molecular Weight Heparin for Cerebral Venous Sinus Thrombosis
por: Kim, Ji Seon, et al.
Publicado: (2005)

Effectiveness and Safety of Rivaroxaban and Low Molecular Weight Heparin in Cancer-Associated Venous Thromboembolism
por: Coleman, Craig I., et al.
Publicado: (2023)

Effect of heparin and low-molecular weight heparin on serum potassium and sodium levels
por: Bengalorkar, Girish M., et al.
Publicado: (2011)

Comparison of Low-Molecular-Weight Heparins Prepared From Ovine Heparins With Enoxaparin
por: Chen, Jianle, et al.
Publicado: (2019)

Unfractionated and low molecular weight heparin
por: Lima, Marcelo, et al.
Publicado: (2014)

Heparin: an intervenor in cell communication
por: Xu, Xianxiang, et al.
Publicado: (2010)

Derivation and Validation of Age- and Body Mass Index-Adjusted Weight-Based Unfractionated Heparin Dosing
por: Schurr, James W., et al.
Publicado: (2019)

Clinical outcome with different doses of low-molecular-weight heparin in patients hospitalized for COVID-19
por: Mennuni, Marco G., et al.
Publicado: (2021)

Comparison of modified versus conventional injection techniques of low-molecular-weight heparin in elderly
por: Geng, Wenzhen, et al.
Publicado: (2018)

A meta-analysis of bridging anticoagulation between low molecular weight heparin and heparin
por: Tao, Ende, et al.
Publicado: (2020)

Extended versus inpatient thromboprophylaxis with heparins following major open abdominopelvic surgery for malignancy: a systematic review of efficacy and safety
por: Heijkoop, B., et al.
Publicado: (2020)

Efficacy and safety of low-molecular-weight heparin after knee arthroscopy: A meta-analysis
por: Huang, Hai-Feng, et al.
Publicado: (2018)

Arterial indications for the low molecular weight heparins
por: Ageno, Walter, et al.
Publicado: (2001)

Low dose aspirin and low-molecular-weight heparin in the treatment of pregnant Libyan women with recurrent miscarriage
por: Elmahashi, Mohamed O, et al.
Publicado: (2014)

Use of a fixed, body weight-unadjusted loading dose of unfractionated heparin for extracorporeal cardiopulmonary resuscitation
por: Iwashita, Yoshiaki, et al.
Publicado: (2015)

Safety profile of preoperative administration of low-molecular-weight heparin on minimally invasive lung cancer surgery: a randomized controlled trial
por: A-Lai, Gu-Ha, et al.
Publicado: (2021)

Safety and Pharmacokinetics of Intranasally Administered Heparin
por: Harris, Hannah M., et al.
Publicado: (2022)

Safety and Pharmacokinetics of Intranasally Administered Heparin
por: Harris, Hannah M., et al.
Publicado: (2022)

Low-Molecular-Weight Heparin and Unfractionated Heparin Decrease Th-1, 2, and 17 Expressions
por: Huang, Jing-Ning, et al.
Publicado: (2014)

Is the Incidence Trend of Heparin-Induced Thrombocytopenia Decreased by the Increased Use of Low-Molecular-Weight-Heparin?
por: Al-Eidan, Fahad A S
Publicado: (2015)

Low-molecular-weight heparin compared with unfractionated heparin in critically ill COVID-19 patients
por: Volteas, Panagiotis, et al.
Publicado: (2022)

Heparin, Low Molecular Weight Heparin, and Non-Anticoagulant Derivatives for the Treatment of Inflammatory Lung Disease
por: Shute, Janis Kay
Publicado: (2023)

Catheter ablation versus medical rate control for persistent atrial fibrillation in patients with heart failure: A PRISMA-compliant systematic review and meta-analysis of randomized controlled trials
por: Zhu, Min, et al.
Publicado: (2016)

Efficacy and safety of low molecular weight heparin compared to unfractionated heparin for chronic outpatient hemodialysis in end stage renal disease: systematic review and meta-analysis
por: Palamaner Subash Shantha, Ghanshyam, et al.
Publicado: (2015)

Efficacy and Safety of Low-Molecular-Weight Heparins As An Adjunct to Thrombolysis in Acute ST-Elevation Myocardial Infarction
por: Rubboli, Andrea
Publicado: (2008)

The Safety and Efficacy of Low-Molecular-Weight Heparin in Pregnant Women With Rheumatic Heart Disease and Valves Replacement
por: Alghamdi, Najwa, et al.
Publicado: (2022)

Type and dose of heparin in Covid‐19: Reply
por: Thachil, Jecko, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_1d1j3cq4tsp5dei4qajej9fk37